TY - JOUR
T1 - Impact of the advisory committee on immunization practices' 4-day grace period in a low-income community
AU - Irigoyen, Matilde
AU - LaRussa, Philip
AU - Findley, Sally E.
AU - Chen, Shaofu
AU - Caesar, Arturo
AU - Tesler, Peter
N1 - Funding Information:
This study was supported by Grant U66/CCU212961 from the Centers for Disease Control and Prevention, National Immunization Program. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the funding agency.
PY - 2003
Y1 - 2003
N2 - Background: In 2002, the Advisory Committee on Immunization Practices (ACIP) recommended vaccine doses administered ≤4 days before the minimum age or interval be counted as valid. The study objective was to assess the impact of the 4-day grace period on the need for revaccination and associated costs in a low-income community, compared to standard practice (i.e., repeating all doses that fall outside current ACIP guidelines). Methods: From 1999 to 2001, semi-annual immunization assessments of 8293 randomly selected children, aged 19-35 months, were conducted at a 16-practice network serving an underserved community in New York City. Outcome measures were rates of antigen-specific invalid doses and number of children needing revaccination, with and without the 4-day grace period. Revaccination costs were based on the Vaccines for Children (VFC) price list. Results: The 4-day grace period reduced the number of children needing revaccination from 17.1% to 12.0%, a drop of 30%. The rates of invalid doses decreased from 1.9% to 1.3%, a drop of 33%. Invalid doses for hepatitis B (HepB)-2 decreased by two thirds (69.7%); for diphtheria-tetanus- acellular pertussis (DTaP)-1, Haemophilus influenzae type b (Hib)-1 and Hib-3 by half (44.9%-50.0%); for Polio-1, Polio-2, Polio-3, and measles-mumps-rubella (MMR) by one third (31.6%-33.3%); and for DTaP-2, DTaP-3, HepB-3, and varicella by nearly one quarter (20.0%-24.0%). At these rates, revaccinating 100,000 children younger than age 3 years would cost $213,588 per year, compared to $152,539 with the 4-day grace period, in vaccine costs alone. Conclusions: In a low-income community, ACIP's 4-day grace period made a significant impact on the number of children requiring revaccination and on revaccination costs. However, the number of children needing revaccination remains high.
AB - Background: In 2002, the Advisory Committee on Immunization Practices (ACIP) recommended vaccine doses administered ≤4 days before the minimum age or interval be counted as valid. The study objective was to assess the impact of the 4-day grace period on the need for revaccination and associated costs in a low-income community, compared to standard practice (i.e., repeating all doses that fall outside current ACIP guidelines). Methods: From 1999 to 2001, semi-annual immunization assessments of 8293 randomly selected children, aged 19-35 months, were conducted at a 16-practice network serving an underserved community in New York City. Outcome measures were rates of antigen-specific invalid doses and number of children needing revaccination, with and without the 4-day grace period. Revaccination costs were based on the Vaccines for Children (VFC) price list. Results: The 4-day grace period reduced the number of children needing revaccination from 17.1% to 12.0%, a drop of 30%. The rates of invalid doses decreased from 1.9% to 1.3%, a drop of 33%. Invalid doses for hepatitis B (HepB)-2 decreased by two thirds (69.7%); for diphtheria-tetanus- acellular pertussis (DTaP)-1, Haemophilus influenzae type b (Hib)-1 and Hib-3 by half (44.9%-50.0%); for Polio-1, Polio-2, Polio-3, and measles-mumps-rubella (MMR) by one third (31.6%-33.3%); and for DTaP-2, DTaP-3, HepB-3, and varicella by nearly one quarter (20.0%-24.0%). At these rates, revaccinating 100,000 children younger than age 3 years would cost $213,588 per year, compared to $152,539 with the 4-day grace period, in vaccine costs alone. Conclusions: In a low-income community, ACIP's 4-day grace period made a significant impact on the number of children requiring revaccination and on revaccination costs. However, the number of children needing revaccination remains high.
UR - http://www.scopus.com/inward/record.url?scp=1542464833&partnerID=8YFLogxK
U2 - 10.1016/S0749-3797(03)00194-6
DO - 10.1016/S0749-3797(03)00194-6
M3 - Article
C2 - 14507532
AN - SCOPUS:1542464833
SN - 0749-3797
VL - 25
SP - 245
EP - 250
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
IS - 3
ER -